News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘LungCancer’ clear

  • A simple blood test can rapidly and accurately detect mutations in two key genes in non-small cell lung tumors, researchers at Dana-Farber Cancer Institute report in a new study.

Tags: LungCancer

  • If you’re a lung or colorectal cancer patient, your finances could determine your level of suffering and quality of life during treatment, according to a new study by Dana-Farber Cancer Institute researchers.

Tags: ColonCancer, LungCancer

  • Three Dana-Farber researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.

Tags: ColonCancer, EndOfLife, LungCancer

  • New treatments for leukemia, colorectal cancer, brain cancer, lung cancer and breast cancer topped the list of most important research and clinical developments at Dana-Farber in 2015.

Tags: BreastCancer, ColonCancer, LungCancer, Leukemia, BrainTumors

  • Non-small cell lung cancer (NSCLC) in younger patients is a distinct disease, genetically and biologically, from NSCLC in older patients and may require a different treatment approach, Dana-Farber Cancer Institute scientists have found.

Tags: LungCancer

  • In a span of five weeks beginning in late October, the U.S. Food and Drug Administration (FDA) gave approval to five new cancer drugs that proved effective in Dana-Farber-led clinical trials – and, in some cases, derive from basic research in Dana-Farber laboratories.

Tags: chemotherapy, BasicResearch, LungCancer, MultipleMyeloma, Sarcoma

  • After identifying three different types of resistance to a promising investigational lung cancer drug, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors’ constant and varied molecular shape-shifting.

Tags: LungCancer

  • A study led by Pasi Jänne, MD, PhD, found that an experimental drug targeted to the resistance mutation is highly active in patients with EGFR-positive non-small cell lung cancer (NSCLC) when the disease progressed during treatment with front-line inhibitor drugs.

Tags: LungCancer, Genetics

  • Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

Tags: EGFR, Genomics, LungCancer, OvarianCancer, ProstateCancer, Lymphoma, Immunotherapy

  • Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

Tags: Genomics, LungCancer

Showing 1-10 of 41 items